Pravibismane | CAS#175880-68-9 | antibacterial

Pravibismane
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584816

CAS#: 175880-68-9

Description: Pravibismane, also known as BisEDT, MBN 101, is an antibacterial agent against a broad range of gram-positive and gram-negative pathogens.liposomal bismuth-ethanedithiol-loaded tobramycin (LipoBiEDT-TOB reduced the production of quorum-sensing molecules and virulence factors and could highly improve the management of chronic pulmonary infection in cystic fibrosis patients.

Chemical Structure

Pravibismane

CAS# 175880-68-9

Instruction

Theoretical Analysis

MedKoo Cat#: 584816
Name: Pravibismane
CAS#: 175880-68-9
Chemical Formula: C6H12Bi2S6
Exact Mass: 693.89
Molecular Weight: 694.483
Elemental Analysis: C, 10.38; H, 1.74; Bi, 60.18; S, 27.70

Price and Availability

Size	Price	Availability
5mg	USD 90	Ready to ship
10mg	USD 160	Ready to ship
25mg	USD 350	Ready to ship
50mg	USD 550	Ready to ship
100mg	USD 950	Ready to ship
200mg	USD 1650	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Pravibismane; BisEDT; MBN 101; MBN-101; MBN101; Bismuth ethanedithiol;

IUPAC/Chemical Name: 2,2'-[ethane-1,2-diylbis(sulfanediyl)]bis(1,3,2-dithiabismolane)

InChi Key: GUTNLKRPYCTIHX-UHFFFAOYSA-H

InChi Code: InChI=1S/3C2H6S2.2Bi/c3*3-1-2-4;;/h3*3-4H,1-2H2;;/q;;;2*+3/p-6

SMILES Code: [Bi]1(SCCS[Bi]2SCCS2)SCCS1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Certificate of Analysis:

View CoA: current batch, Lot#S21S08C30

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	Antibacterial agent against a broad range of gram-positive and gram-negative pathogens.
In vitro activity:	B. multivorans and B. cenocepacia showed a wide range of susceptibilities to BTs. Bismuth ethanedithiol (BisEDT) was one of the more potent BTs against these organisms (MIC50 7.8 microM), and was selected for synergy studies. Selected strains were highly resistant to tobramycin. The addition of subinhibitory concentrations of BisEDT (2 microM) reduced the MIC and MBC of tobramycin against all strains, achieving synergy in many instances. The FIC index was in the range 0.28-0.66 and the FBC in the range 0.12-0.85. Most strains became susceptible to tobramycin at clinically achievable concentrations in the presence of non-toxic BisEDT levels. Reference: Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E, Kazzaz JA. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother. 2003 Dec;52(6):915-9. doi: 10.1093/jac/dkg471. Epub 2003 Oct 29. PMID: 14585856.
In vivo activity:	The quorum-sensing signal molecule N-acyl homoserine lactone was monitored by using a biosensor organism. P. aeruginosa virulence factors were assessed spectrophotometrically. An agar beads model of chronic Pseudomonas lung infection in rats was used to evaluate the efficacy of the liposomal formulation in the reduction of bacterial count. The levels of active tobramycin in the lungs and the kidneys were evaluated by microbiological assay. LipoBiEDT-TOB was effective in disrupting both quorum-sensing signal molecules N-3-oxo-dodeccanoylhomoserine lactone and N-butanoylhomoserine lactone, as well as significantly (P < 0.05) reducing lipase, chitinase, and protease production. At 24 h after 3 treatments, the CFU counts in lungs of animals treated with LipoBiEDT-TOB were of 3 log(10) CFU/lung, comparated to 7.4 and 4.7 log(10) CFU/lung, respectively, in untreated lungs and in lungs treated with free antibiotic. The antibiotic concentration after the last dose of LipoBiEDT-TOB was 25.1 μg/lung, while no tobramycin was detected in the kidneys. As for the free antibiotic, we found 6.5 μg/kidney but could not detect any tobramycin in the lungs. Taken together, LipoBiEDT-TOB reduced the production of quorum-sensing molecules and virulence factors and could highly improve the management of chronic pulmonary infection in cystic fibrosis patients. Reference: Alhariri M, Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2013 Jan;57(1):569-78. doi: 10.1128/AAC.01634-12. Epub 2012 Nov 12. PMID: 23147741; PMCID: PMC3535983.

Preparing Stock Solutions

The following data is based on the product molecular weight 694.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E, Kazzaz JA. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother. 2003 Dec;52(6):915-9. doi: 10.1093/jac/dkg471. Epub 2003 Oct 29. PMID: 14585856.
In vitro protocol:	Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E, Kazzaz JA. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother. 2003 Dec;52(6):915-9. doi: 10.1093/jac/dkg471. Epub 2003 Oct 29. PMID: 14585856.
In vivo protocol:	Alhariri M, Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2013 Jan;57(1):569-78. doi: 10.1128/AAC.01634-12. Epub 2012 Nov 12. PMID: 23147741; PMCID: PMC3535983.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Mahdiun F, Mansouri S, Khazaeli P, Mirzaei R. The effect of tobramycin incorporated with bismuth-ethanedithiol loaded on niosomes on the quorum sensing and biofilm formation of Pseudomonas aeruginosa. Microb Pathog. 2017 Jun;107:129-135. doi: 10.1016/j.micpath.2017.03.014. Epub 2017 Mar 18. PMID: 28323149.

2: Alhariri M, Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2013 Jan;57(1):569-78. doi: 10.1128/AAC.01634-12. Epub 2012 Nov 12. PMID: 23147741; PMCID: PMC3535983.

3: Alipour M, Dorval C, Suntres ZE, Omri A. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. J Pharm Pharmacol. 2011 Aug;63(8):999-1007. doi: 10.1111/j.2042-7158.2011.01304.x. Epub 2011 Jun 15. PMID: 21718282.

4: Alipour M, Suntres ZE, Lafrenie RM, Omri A. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth- ethanedithiol with tobramycin in liposomes. J Antimicrob Chemother. 2010 Apr;65(4):684-93. doi: 10.1093/jac/dkq036. Epub 2010 Feb 15. PMID: 20159770.

5: Halwani M, Blomme S, Suntres ZE, Alipour M, Azghani AO, Kumar A, Omri A. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int J Pharm. 2008 Jun 24;358(1-2):278-84. doi: 10.1016/j.ijpharm.2008.03.008. Epub 2008 Mar 15. PMID: 18448284.

6: Domenico P, Gurzenda E, Giacometti A, Cirioni O, Ghiselli R, Orlando F, Korem M, Saba V, Scalise G, Balaban N. BisEDT and RIP act in synergy to prevent graft infections by resistant staphylococci. Peptides. 2004 Dec;25(12):2047-53. doi: 10.1016/j.peptides.2004.08.005. PMID: 15572191.

7: Wu CL, Domenico P, Hassett DJ, Beveridge TJ, Hauser AR, Kazzaz JA. Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2002 Jun;26(6):731-8. doi: 10.1165/ajrcmb.26.6.2001-00020oc. PMID: 12034573.

8: Veloira WG, Domenico P, LiPuma JJ, Davis JM, Gurzenda E, Kazzaz JA. In vitro activity and synergy of bismuth thiols and tobramycin against Burkholderia cepacia complex. J Antimicrob Chemother. 2003 Dec;52(6):915-9. doi: 10.1093/jac/dkg471. Epub 2003 Oct 29. PMID: 14585856.

Your view history

Pravibismane new featured